ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1983

Prevalence Of Birefringent Crystals In Three Inflammation-Prone Tissues

Jane Park1, Divya Soman2, Martine P. Roudier3 and Peter A. Simkin4, 1Rheumatology, University of Washington, Seattle, WA, 2University of Washington, Seattle, WA, 3Pathology, University of Washington, Seattle, WA, 4Div of Rheumatology, University of Washington, Seattle, WA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, Comorbidity, Gout and uric acid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Metabolic and Crystal Arthropathies II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

When serum is hyperuricemic, so too are all interstitial fluids other than CSF and sweat.  Anecdotally, urate crystals deposit as grossly visible tophi in many non-articular organs, including cardiac valves, but no microscopic studies of crystal prevalence have been done at those sites.  Are the tophi unique, or are they the tip of a crystalline iceberg?  Evidence from new imaging modalities including dual energy CT and ultrasound suggest that they may be surprisingly common.

Just as urate crystals drive gouty arthritis, such deposits may be a factor in extraarticular inflammation.  Higher urate levels within prostatic secretions have correlated with symptoms of chronic prostatitis, and a single placebo-controlled study found that allopurinol decreased prostatic urate secretion and improved subjective pain.  In addition, gout and hyperuricemia are now accepted as independent risk factors for coronary artery disease and all-cause mortality, and allopurinol use may lead to decreased mortality.  The cardiac risk has been attributed to hyperuricemia, but the possibility of arterial urate crystals has not been considered.  If present, such crystals could cause intimal inflammation leading to coronary thrombosis.  To investigate this possibility, we used polarizing microscopy to examine tissues from 3 sites of enigmatic inflammation: coronary arteries, cardiac valves, and prostates.

Methods:

Tissues were:  1.  Alcohol-fixed and H&E stained coronary arteries (left anterior descending, right coronary, and circumflex) from 50 explanted hearts collected from 2000-2003.  2.  Twenty-three alcohol-fixed, unstained aortic valves from replacement surgery done in 2011-2013.  3.  Frozen, unstained, non-malignant regions of 40 consecutive prostatectomies for cancer in 2012-2013.  Clinical data regarding gout and hyperuricemia were unavailable or incomplete for all subjects.

Results:

Tissue

Source

Gender

Age

N

Number of positive specimens

% positive

Coronary

Explant

M + F

Any

50

6

12%

Prostate

Cancer surgery

M

61.2 ± 7.2

40

19

47.5%

Aortic valve

Explant

M + F

62.3  ± 17.0

23

1

4.3%

Conclusion:

We have observed birefringent crystals, primarily negatively so, in 12% of coronary arteries, 48% of prostates, and 4% aortic valves examined thus far.  Alcohol fixation, rather than formalin which is known to dissolve urate crystals, and polarizing microscopy are necessary in order to recognize urate crystals in pathologic tissues. 

“Gouty arteritis” should be considered as a possible factor in ischemic heart disease.  We hope these tools will be applied by pathologists conducting autopsies on patients who have suffered fatal myocardial infarctions.  In addition, if our preliminary findings are confirmed within the prostate, further studies will be indicated with urate lowering agents and anti-inflammatory drugs known to be effective in gouty arthritis. 


Disclosure:

J. Park,

Takeda Pharmaceuticals,

2;

D. Soman,
None;

M. P. Roudier,
None;

P. A. Simkin,

Takeda Pharmaceuticals,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-birefringent-crystals-in-three-inflammation-prone-tissues/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology